Efficacy of Atomoxetine in Adult Attention-deficit/hyperactivity Disorder: a Drug-placebo Response Curve Analysis

Overview

Journal Behav Brain Funct

Publisher Biomed Central

Specialties Neurology
Psychology
Social Sciences

Date 2005 Oct 6

PMID 16202140

Citations 18

Authors

Stephen V Faraone

Joseph Biederman

Thomas Spencer

David Michelson

Lenard Adler

Fred Reimherr

Stephen J Glatt

Affiliations

Soon will be listed here.

Abstract

Background: The objective of this study was to evaluate the efficacy of atomoxetine, a new and highly selective inhibitor of the norepinephrine transporter, in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) among adults by using drug-placebo response curve methods.

Methods: We analyzed data from two double-blind, placebo-controlled, parallel design studies of adult patients (Study I, N = 280; Study II, N = 256) with DSM-IV-defined ADHD who were recruited by referral and advertising. Subjects were randomized to 10 weeks of treatment with atomoxetine or placebo, and were assessed with the Conners Adult ADHD Rating Scales and the Clinical Global Impression of ADHD Severity scale before and after treatment.

Results: Those treated with atomoxetine were more likely to show a reduction in ADHD symptoms than those receiving placebo. Across all measures, the likelihood that an atomoxetine-treated subject improved to a greater extent than a placebo-treated subject was approximately 0.60. Furthermore, atomoxetine prevented worsening of most symptom classes.

Conclusion: From these findings, we conclude that atomoxetine is an effective treatment for ADHD among adults when evaluated using several criteria.

Citing Articles

Mood Stabilizers for Treating Emotional Dysregulation in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) with or Without Comorbid Bipolar Spectrum Disorders.

Brancati G, De Rosa U, Magnesa A, De Dominicis F, Petrucci A, Schiavi E Brain Sci. 2025; 15(2).

PMID: 40002515 PMC: 11853101. DOI: 10.3390/brainsci15020182.

Trait Impulsivity as a Feature of Parkinson's Disease Treatment and Progression.

Spencer H, Anderton R Parkinsons Dis. 2024; 2024:8770997.

PMID: 38766569 PMC: 11102119. DOI: 10.1155/2024/8770997.

Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.

Fox H, Sofuoglu M, Sinha R J Psychopharmacol. 2015; 29(3):312-23.

PMID: 25567555 PMC: 4432477. DOI: 10.1177/0269881114562464.

Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants.

Weyandt L, Oster D, Marraccini M, Gudmundsdottir B, Munro B, Zavras B Psychol Res Behav Manag. 2014; 7:223-49.

PMID: 25228824 PMC: 4164338. DOI: 10.2147/PRBM.S47013.

Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models.

Jupp B, Dalley J Br J Pharmacol. 2014; 171(20):4729-66.

PMID: 24866553 PMC: 4209940. DOI: 10.1111/bph.12787.

References

Michelson D, Adler L, Spencer T, Reimherr F, West S, Allen A . Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003; 53(2):112-20. DOI: 10.1016/s0006-3223(02)01671-2. View

Wernicke J, Kratochvil C . Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2003; 63 Suppl 12:50-5. View

Siegel B, Vukicevic J, Spitzer R . Using signal detection methodology to revise DSM-III-R: re-analysis of the DSM-III-R national field trials for autistic disorder. J Psychiatr Res. 1990; 24(4):293-311. DOI: 10.1016/0022-3956(90)90002-8. View

Faraone S, Short E, Biederman J, Findling R, Roe C, Manos M . Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. Int J Neuropsychopharmacol. 2002; 5(2):121-9. DOI: 10.1017/S1461145702002845. View

Siegel B, Vukicevic J, Elliott G, Kraemer H . The use of signal detection theory to assess DSM-III-R criteria for autistic disorder. J Am Acad Child Adolesc Psychiatry. 1989; 28(4):542-8. DOI: 10.1097/00004583-198907000-00013. View

Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J . Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998; 155(5):693-5. DOI: 10.1176/ajp.155.5.693. View

Faraone S, Pliszka S, Olvera R, Skolnik R, Biederman J . Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology. J Child Adolesc Psychopharmacol. 2001; 11(2):171-80. DOI: 10.1089/104454601750284081. View

McNeil B, Hanley J . Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making. 1984; 4(2):137-50. DOI: 10.1177/0272989X8400400203. View

Hanley J, McNeil B . The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143(1):29-36. DOI: 10.1148/radiology.143.1.7063747. View

10.

Colditz G, Miller J, Mosteller F . Measuring gain in the evaluation of medical technology. The probability of a better outcome. Int J Technol Assess Health Care. 1987; 4(4):637-42. DOI: 10.1017/s0266462300007728. View

11.

Faraone S, Biederman J, Spencer T, Wilens T . The drug-placebo response curve: a new method for assessing drug effects in clinical trials. J Clin Psychopharmacol. 2000; 20(6):673-9. DOI: 10.1097/00004714-200012000-00014. View

12.

Swets J . Sensitivities and specificities of diagnostic tests. JAMA. 1982; 248(5):548-50. View

13.

Fuller R, Wong D . Effects of antidepressants on uptake and receptor systems in the brain. Prog Neuropsychopharmacol Biol Psychiatry. 1985; 9(5-6):485-90. DOI: 10.1016/0278-5846(85)90006-5. View